NeuraLight Reaches Key Milestone with Completion of International Multicenter Parkinson’s Clinical Trial
NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard clinical Parkinson’s assessments. The 12-month, multi-center longitudinal study had a cohort of 300 participants across multiple clinical sites, making it one of the largest longitudinal clinical trials using eye-movement biomarkers to follow disease progression in patients with Parkinson’s over time.
NeuraLight Reveals the World-Class Scientific Leaders Helping to Advance Its Transformation of Disease Progression Measurement in Neurology
NeuraLight, the leader in developing precision biomarkers for neurological disease, today announced that Prof. Thomas Südhof, a Nobel Prize-winning neuroscientist and one of the world’s leading Alzheimer’s disease researchers, has been named Scientific Co-founder of the company and joined its Scientific Advisory Board. This follows the announcement that world-recognized neurologist Prof. Olivier Rascol, a co-creator of the current gold standard for measuring Parkinson’s disease progression (MDS-UPDRS), will head the board.
NeuraLight and CHDI Foundation Collaborate to Develop Precision Eye Movement Biomarkers for Huntington's Disease
NeuraLight, a healthtech company that derives precision biomarkers in neurology, has announced a collaboration with CHDI Foundation—a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington’s disease (HD)—to address the need for novel, sensitive, reliable endpoints for clinical trials.
